FDA Pregnancy and Lactation Labeling for Semaglutide Semaglutide's prescribing information places it in a cautious category for breastfeeding: the FDA notes that animal reproduction studies showed fetal harm, and human lactation data is unavailable
Clinically, as currently the most common form of HF, HFpEF is characterized by ventricular hypertrophy and myocardial fibrosis, with signs of respiratory distress and congestion in most patients [6]
Contact your GP or healthcare provider if you experience: Severe or worsening joint pain that interferes with daily activities or does not improve with simple measures Joint swelling, redness, or warmth , which may indicate inflammation or infection Sudden onset of intense pain in a single joint, particularly if accompanied by fever (may require same-day assessment to exclude septic arthritis or gout) Joint pain associated with systemic symptoms such as unexplained fever, weight loss (beyond expected treatment effects), rash, or general malaise Persistent pain lasting more than two weeks despite self-care measures Joint stiffness lasting more than 30 minutes after waking , which may suggest inflammatory arthritis Reduced range of motion or inability to bear weight on affected joints Seek urgent medical attention (contact 111 or attend A&E) if: Joint pain is accompanied by severe abdominal pain, persistent vomiting, or signs of pancreatitis (if pancreatitis is suspected, stop your GLP-1 medication immediately
This suggests that the medication treats the patient holistically rather than isolating a single symptom
Pfeffer MA, et al
37% falsely suggested FDA approval, while 14% failed to clarify they were offering compounded versions
